The canine histiocytic diseases represent a complex of diseases originating from myeloid dendritic cells.3 Although originating from a common precursor, the benign and malignant counterparts of the histiocytic disease spectrum are vastly different in biologic behavior, recommended treatment, and prognosis. Recognizing the breed and age predilections for this spectrum of clinical diseases is paramount to identifying cases that require a diagnostic workup. Immunohistochemical analysis is beneficial in solidifying an accurate diagnosis so that appropriate therapy can be instituted promptly, as aggressive early treatment can improve survival times in dogs with histiocytic sarcoma. Recent retrospective analyses have shown promise for combination therapy, including radiation therapy and chemotherapy to treat histiocytic sarcoma. Controlled, prospective studies are warranted to determine the appropriate treatment of histiocytic sarcoma.
|Original language||English (US)|
|Number of pages||17|
|State||Published - Jul 2007|
ASJC Scopus subject areas
- Small Animals